Conventional wisdom holds that, with the exception of skin and blood cells, most tissues in the body do not normally regenerate. But recent research has uncovered some surprising biological mechanisms that indicate that the body does in fact have the potential to repair some other vital tissues. Hoping to exploit this work, a Harvard University and University of Utah startup, Hydra BioSciences, is seeking to develop drugs that it says will repair damage from heart attacks.
Hydra’s focus is on heart attack survivors-a group joined by hundreds of thousands of people in the United States every year-who are often left with damaged, scarred cardiac tissue that could lead to complete heart failure later in life. Current drugs don’t repair the tissue, so Hydra is working on new treatments that will nudge mature heart-muscle cells to multiply again and ultimately form new, beating muscle. The three-year-old company’s first project is to develop drugs that would be given to patients within a few weeks after a heart attack to trigger regrowth of the healthy cells near the injured area and prevent the heart from weakening and scarring. A similar therapeutic strategy could eventually work for a wide range of ailments and injuries, such as type I diabetes, retinal degeneration, spinal-cord injury, and Parkinson’s disease, says Mark Keating, Hydra’s cofounder and a researcher at Children’s Hospital Boston.
In January, Hydra raised almost $19 million in second-round venture financing. And it has also made progress on discovering drug candidates. It recently isolated a protein that may stimulate cell growth in the heart and hopes to begin testing it in animals by the beginning of next year. “If this works, we can regenerate the heart and create newer, younger, better cells,” says Piero Anversa, director of the Cardiovascular Research Institute at the New York Medical College.
This new data poisoning tool lets artists fight back against generative AI
The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models.
The Biggest Questions: What is death?
New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.
Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist
An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.
How to fix the internet
If we want online discourse to improve, we need to move beyond the big platforms.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.